These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24325991)

  • 21. [Chronic kidney disease (CKD) and bone. The mechanisms of chronic kidney disease--mineral and bone disorder (CKD-MBD)].
    Hamada Y; Fukagawa M
    Clin Calcium; 2009 Apr; 19(4):486-92. PubMed ID: 19329826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD.
    Jovanovich A; Isakova T; Block G; Stubbs J; Smits G; Chonchol M; Miyazaki M
    Am J Kidney Dis; 2018 Jan; 71(1):27-34. PubMed ID: 28801122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New Developments in CKD-MBD. Strategies for the management of predilalysis CKD-MBD].
    Ando R
    Clin Calcium; 2014 Dec; 24(12):1845-51. PubMed ID: 25423931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of mineral bone disorder with pharmaceuticals which influence the calcium phosphor turnover].
    Vestergaard P; Eiken PA
    Ugeskr Laeger; 2012 Nov; 174(47):2931-4. PubMed ID: 23171790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone and kidney disease: diagnostic and therapeutic implications.
    Jamal SA; West SL; Miller PD
    Curr Rheumatol Rep; 2012 Jun; 14(3):217-23. PubMed ID: 22350608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
    J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multinational observational study on clinical practices and therapeutic management of mineral and bone disorders in patients with chronic kidney disease stages 4, 5, and 5D: The OCEANOS study.
    Shaheen FA; Kurpad R; Al-Sayyari AA; Souqiyyeh MZ; Aljubori H; El Baz T; Kashif W; Tuganbekova S; Kabulbayev K; Jarraya F; Nafar M
    Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):290-304. PubMed ID: 26997382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric CKD-MBD: existing and emerging treatment approaches.
    Ayoob RM; Mahan JD
    Pediatr Nephrol; 2022 Nov; 37(11):2599-2614. PubMed ID: 35038008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Updates on Lifestyle-Related Diseases and Bone Metabolism. CKD-related osteoporosis].
    Yamada S; Inaba M
    Clin Calcium; 2014 Nov; 24(11):1605-13. PubMed ID: 25355144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Therapy in CKD Patients Can Affect Vitamin K Status.
    Cozzolino M; Cianciolo G; Podestà MA; Ciceri P; Galassi A; Gasperoni L; Manna G
    Nutrients; 2020 May; 12(6):. PubMed ID: 32486167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic kidney disease is associated with low BMD at the hip but not at the spine.
    Bezerra de Carvalho KS; Vasco RFV; Custodio MR; Jorgetti V; Moysés RMA; Elias RM
    Osteoporos Int; 2019 May; 30(5):1015-1023. PubMed ID: 30693381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
    Neven E; Vervaet B; Brand K; Gottwald-Hostalek U; Opdebeeck B; De Maré A; Verhulst A; Lalau JD; Kamel S; De Broe ME; D'Haese PC
    Kidney Int; 2018 Jul; 94(1):102-113. PubMed ID: 29716795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of mineral and bone disorder after kidney transplantation.
    Kalantar-Zadeh K; Molnar MZ; Kovesdy CP; Mucsi I; Bunnapradist S
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):389-403. PubMed ID: 22614626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
    Ota M; Takahata M; Shimizu T; Kanehira Y; Kimura-Suda H; Kameda Y; Hamano H; Hiratsuka S; Sato D; Iwasaki N
    Osteoporos Int; 2017 Apr; 28(4):1481-1490. PubMed ID: 27933339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease.
    Miller PD
    Curr Osteoporos Rep; 2005 Mar; 3(1):5-12. PubMed ID: 16036095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient.
    Heaf JG
    Perit Dial Int; 2015 Nov; 35(6):640-4. PubMed ID: 26702005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Osteoporosis in CKD.
    Khairallah P; Nickolas TL
    Clin J Am Soc Nephrol; 2018 Jun; 13(6):962-969. PubMed ID: 29487093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.